期刊
MOLECULAR MEDICINE REPORTS
卷 4, 期 6, 页码 1273-1278出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/mmr.2011.557
关键词
ovarian cancer; p16; hMLH1; MGMT; epigenetic; DNA methylation; histone acetylation
资金
- Scientific Research Foundation [20091112]
To investigate the contributions of histone H3 lysine 9 acetylation and DNA methylation to p16, hMLH1 and MGMT silencing in ovarian cancer cells, we treated three ovarian cancer cell lines with Trichostatin A (TSA) and 5-aza-2'-deoxycytidine and examined the status of mRNA expression, DNA methylation and histone H3 lysine 9 acetylation at the promoter of p16, hMLH1 and MGMT. The results showed that the hypermethylated silenced tumor-related genes in the ovarian cancer cells were characterized by hypoacetylated histone H3 lysine 9. Treatment with TSA resulted in the increase of histone H3 lysine 9 acetylation at the hypermethylated promoter, but with little effects on gene expression. TSA did not contribute to DNA demethylation. 5-Aza-2'-deoxycytidine treatment caused DN.A demethylation, increased histone H3 lysine 9 acetylation at the hypermethylated promoter and resulted in reactivation of p16, hMLH1 and MGMT. Combined treatments synergistically increased histone H3 lysine 9 acetylation accompanied by the re-expression of the hypermethylated genes. To conclude, in ovarian cancer cells, DNA methylation and histone deacetylation act synergistically for the silencing of cancer-associated genes. DNA demethylation is superior to histone acetylation for reactivating cancer-associated genes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据